Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven
about
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.Modifying Dendritic Cell Activation with Plasmonic Nano VectorsAntitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate bindingPolycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.Tumour thermotolerance, a physiological phenomenon involving vessel normalisationMicrobeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptideGalectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy.Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.Galectin-1 inhibitors and their potential therapeutic applications: a patent review.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven.Observations in the Synthesis of the Core of the Antitumor Illudins via an Enyne Ring Closing Metathesis CascadeGalectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems.Combination of anginex gene therapy and radiation decelerates the growth and pulmonary metastasis of human osteosarcoma xenografts.Galectins as Molecular Targets for Therapeutic Intervention.Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry
P2860
Q30430457-75F907E4-8AFD-47E9-866B-B011542C4464Q33906222-46BD4E83-2A6F-40D2-B22E-4207F06921AEQ34564173-EC3E317D-19DA-4F55-8400-3E1ACF6742F6Q34564225-5836813F-3400-4E78-972B-E77DA1DFAC60Q34564433-49F406DB-B6DB-4CBF-853A-CED84E428D9DQ34916042-6CFED3B7-234C-4130-9727-A3D0976A1510Q36082119-4BCB00BD-A080-41CD-B97D-C40833C4D6B6Q36379734-874AFED8-B67C-4A06-B952-43B214970E48Q36642433-261AF44F-6ACD-4F68-8BF1-8C5EF36FF851Q38763827-600D00C4-1DDD-4ADA-8CB4-CA4CAD70E1ADQ39205186-1CB8333B-00FE-4953-B502-BC146681A80CQ41865123-7871088E-CA25-48CD-B435-0CAC35EBC961Q42590408-01902105-D776-46D3-8BB5-52B52130125BQ48270428-A0849A8E-BAFF-43D3-974F-78764F0CAF8AQ54995893-DB75ABF8-F8C5-44C3-9254-79DCC5004961Q55283741-89CB8536-706F-4EBC-83E8-75F58D0007DFQ55316400-094184AB-1B7A-4307-8C32-CE44740E9E75Q57961571-086072E5-5BB8-429B-B50B-89D5783F2519
P2860
Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@ast
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@en
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@nl
type
label
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@ast
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@en
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@nl
prefLabel
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@ast
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@en
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@nl
P2093
P2860
P1433
P1476
Ovarian tumor growth regressio ...... the chemotherapeutic irofulven
@en
P2093
Emily S Van Laar
Jeremy Webber
John R MacDonald
Kevin H Mayo
Robert J Griffin
Ruud P M Dings
Stephen J Waters
P2860
P304
P356
10.1016/J.CANLET.2008.02.048
P407
P577
2008-04-01T00:00:00Z